Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up.

Regarding cardio-pulmonary health, the patient was followed within the prospective observational multicenter COVID study to investigate long-term sequelae in patients hospitalized for SARS-CoV-2 infection (NCT 04416100) that was approved by the local ethics committee (EK 1103/2020). Maintenance of standard immunosuppressive treatment is recommended in mild-to-moderate disease [[7]]; however, information about the management and outcome of patients with severe generalized MG treated with immune-depleting agents such as rituximab is still limited. Dear Sirs, Novel Corona Virus Disease 2019 (COVID-19) poses an unpredictable risk for patients with myasthenia gravis (MG) due to potentially additive effects of bulbar and respiratory muscle weakness and viral lung affection [[1]]. [Extracted from the article]